Related Experiment Videos
Intermediate dose of intravenous melphalan in advanced multiple myeloma
S Tsakanikas1, K Papanastasiou, M Stamatelou
1Greek Anticancer Institute, Athens.
Abstract:
Eighteen patients with advanced multiple myeloma resistant to VAD chemotherapy (vincristine, Adriamycin, dexamethasone) were treated with intravenous melphalan in a single-pulse dose of 50-70 mg/m2. Objective response (greater than or equal to 50% reduction of the monoclonal protein) was observed in 9 patients. The median duration of remission in the responding patients was 6 months and the median survival 11.5 months. The main toxicity noted was bone marrow suppression. We conclude that intermediate doses of intravenous melphalan are a useful therapeutic modality in refractory or relapsing myeloma patients.
Insights
Intravenous melphalan offers a useful treatment option for advanced multiple myeloma patients resistant to VAD chemotherapy. This approach showed objective responses in half of the patients, with manageable side effects.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Advanced multiple myeloma often becomes resistant to standard treatments like VAD chemotherapy.
- Identifying effective salvage therapies is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of intravenous melphalan as a salvage therapy in multiple myeloma patients refractory to VAD chemotherapy.
Main Methods:
- Eighteen patients with advanced, VAD-resistant multiple myeloma received a single intravenous pulse of melphalan (50-70 mg/m2).
- Objective response was defined as a ≥50% reduction in monoclonal protein levels.
Main Results:
- Nine out of 18 patients (50%) achieved an objective response.
- The median duration of remission was 6 months, and median survival was 11.5 months.
- The primary toxicity observed was bone marrow suppression.
Conclusions:
- Intermediate-dose intravenous melphalan is a viable therapeutic option for relapsed or refractory multiple myeloma.
- This treatment can induce objective responses and prolong survival in heavily pretreated patients.